It's important to check with your health care provider to determine if participating in a clinical trial is right for you. Learn more about clinical trials, what questions to ask before participating and the drug approval process.
Clinical trials play an important role in the development of new and better treatments for psoriasis and psoriatic arthritis. Through clinical trials, companies can learn what treatments are safe and effective for psoriatic diseases, and possibly bring those drugs to the marketplace.
The purpose of this research study is to investigate the safety and effectiveness of an oral drug for people with moderate to severe psoriasis. All study drug and care will be provided at no cost to you if you qualify. Please call to learn more about this study at 1-877-996-6288.
Condition: Plaque psoriasis | Minimum Age: 18 | Phase of Study: Phase 1
A randomized, double-blind, placebo and positive controlled, single and multiple dose study to assess the safety, tolerability, pharmacokinetics and pharmacodynamics of CJM112 in chronic plaque-type psoriasis patients.
Condition: Chronic Plaque-type Psoriasis | Phase: Phase 1/Phase 2 | Minimum Age: 18 Years
The study aims to establish whether defects in immune cell function are shared across multiple autoimmune diseases and whether those problems match to similar genes in the cells.
Condition: Type 1 Diabetes Mellitus | Phase: N/A | Minimum Age: 8 Years
The purpose of this study is to investigate the efficacy and safety of two dose levels of certolizumab pegol compared to active comparator and placebo in adults with moderate to severe chronic plaque psoriasis.
Condition: Psoriasis | Phase: Phase 3 | Minimum Age: 18 Years
Psoriatic arthritis is a heterogeneous chronic inflammatory disorder involving joints, tendon sheaths, entheses, and the axial skeleton as well as skin and nails. This is an open-label trial with H.P. Acthar Gel (80 units/1mL) Subcutaneous injection administered twice weekly. To evaluate the signs and symptoms of psoriatic arthritis after 12 weeks, including American College of Rheumatology 20,Clinical Disease Activity Index, Disease Activity Index 28, Dactylitis and adverse events.
Condition: Psoriatic Arthritis | Phase: Phase 4 | Minimum Age: 18 Years
This study is being done to evaluate the safety, tolerability, activity, pharmacokinetics (PK), and daily dose regimen of KD025 administered orally for 12 weeks to subjects with psoriasis vulgaris who have failed at least one line of systemic therapy.
Condition: Psoriasis Vulgaris | Phase: Phase 2 | Minimum Age: 18 Years